Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more
Astec LifeSciences Limited (ASTEC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.036x
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) has a cash flow conversion efficiency ratio of -0.036x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-83.99 Million) by net assets (₹2.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Astec LifeSciences Limited - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Astec LifeSciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astec LifeSciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inter Pharma Public Company Limited
BK:IP
|
0.036x |
|
Agile Content SA
MC:AGIL
|
-0.035x |
|
Bcl Industries Limited
NSE:BCLIND
|
0.021x |
|
PT Wintermar Offshore Marine Tbk
F:W6O
|
0.027x |
|
Osmanli Menkul Degerler AS
IS:OSMEN
|
-0.129x |
|
BLS E-Services Limited
NSE:BLSE
|
N/A |
|
Woongjin Thinkbig Co Ltd
KO:095720
|
0.118x |
|
Space Shuttle Hi-Tech Co Ltd
TW:2440
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Astec LifeSciences Limited (2008–2025)
The table below shows the annual cash flow conversion efficiency of Astec LifeSciences Limited from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹2.35 Billion | ₹-83.99 Million | -0.036x | -229.20% |
| 2024-03-31 | ₹3.70 Billion | ₹102.21 Million | 0.028x | -84.46% |
| 2023-03-31 | ₹4.20 Billion | ₹746.56 Million | 0.178x | +199.02% |
| 2022-03-31 | ₹3.97 Billion | ₹236.04 Million | 0.060x | +325.51% |
| 2021-03-31 | ₹3.09 Billion | ₹-81.62 Million | -0.026x | -103.87% |
| 2020-03-31 | ₹2.47 Billion | ₹1.68 Billion | 0.682x | +805.15% |
| 2019-03-31 | ₹2.03 Billion | ₹152.85 Million | 0.075x | -80.20% |
| 2018-03-31 | ₹1.70 Billion | ₹646.75 Million | 0.381x | +173.44% |
| 2017-03-31 | ₹1.38 Billion | ₹192.32 Million | 0.139x | +401.11% |
| 2016-03-31 | ₹1.17 Billion | ₹-54.05 Million | -0.046x | -137.74% |
| 2015-03-31 | ₹1.35 Billion | ₹165.82 Million | 0.122x | -21.96% |
| 2014-03-31 | ₹1.14 Billion | ₹178.19 Million | 0.157x | +1.12% |
| 2013-03-31 | ₹1.06 Billion | ₹164.31 Million | 0.155x | +77.15% |
| 2012-03-31 | ₹987.06 Million | ₹86.48 Million | 0.088x | -48.14% |
| 2011-03-31 | ₹970.25 Million | ₹163.91 Million | 0.169x | +50.01% |
| 2010-03-31 | ₹931.08 Million | ₹104.85 Million | 0.113x | +252.98% |
| 2009-03-31 | ₹325.25 Million | ₹-23.94 Million | -0.074x | -109.22% |
| 2008-03-31 | ₹229.75 Million | ₹183.53 Million | 0.799x | -- |